Xiaohua Wu

13PUBLICATIONS
70CO-AUTHORS
Molecular targetsOncology and carcinogenesis not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Sep 01, 2025
YY1-induced USP43 drives ferroptosis suppression by FASN stabilization and subsequent activation of SLC7A11 in ovarian cancer.

Tianyi Zhao, Xiaojun Chen, Jiangchun Wu

|Jul 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.

Panagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer

|Jun 25, 2025
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study.

Lingfang Xia, Keqiang Zhang, Ying Tang

|Jan 15, 2025
m6A-modified circSTX6 as a key regulator of cervical cancer malignancy via SPI1 and IL6/JAK2/STAT3 pathways.

Xiaotian Han, Lingfang Xia, Yong Wu

|Nov 26, 2024
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.

Christian Marth, Richard G Moore, Mariusz Bidziński

|Jun 21, 2024
Germline Mutational Landscape and Novel Targetable RAD51D Variant in Chinese Patients With Ovarian Cancer.

Zheng Feng, Siyu Chen, Na An

Pageof 3

Frequent Collaborators

3 joint publications

Hao Wen

2 joint publications

Antonio González-Martin

2 joint publications

Ursula A Matulonis

2 joint publications

Bradley J Monk